

Press release

Lund April 17, 2023

Scandinavian ChemoTech's Centre of Excellence for Animal Care in the USA makes profit on TSE in the first year

Already after the first year of offering TSE at Scandinavian ChemoTech's Centre of Excellence in the US, FloridaWild, the veterinary hospital has managed to turn the investment into a profitable business and are ready for a new order of treatment kits.

After finalising the investment of a vetIQure™ device and the TSE technology in February 2022, FloridaWild has turned its investment into a profitable business already after 12 months of operations.

FloridaWild, part of the MVP group, is a veterinary hospital focused on smaller companion animals in DeLand and was the first animal hospital that invested in the TSE technology. FloridaWild is today one of Vetiqure AB's partners for clinical development and R&D projects.

Dr Schrager, the Medical Director at the hospital, is this week with her vet tech nurse, supporting Vetiqure North America at VCS in Cancun, one of the most important oncology conferences in the region (<https://vsso.org/conferences-1/2023/1/6/vssovcs-2023-collaborative-conference-cancun>).

"Tumor Specific Electroporation has met or exceeded our expectations in terms of tumor response, sparing of normal tissue and patient comfort post-treatment. VetIQure AB has given us remarkable support, and the equipment has been completely reliable. We are very pleased to be profitable in our first year, especially as a general hospital rather than an oncology center, making access to this technology financially feasible for a multitude of veterinary facilities", says Dr Pamela Schrager.

"It is a great achievement from the team at FloridaWild and I am very happy that our TSE technology can bring such an added value to their patients and at the same time improve their profit. This shows that our business model works for both us and for our clients", says Mohan Frick, CEO of Scandinavian ChemoTech.

About FloridaWild:

FloridaWild Veterinary Hospital is located in DeLand, Florida. The animal hospital's top-of-line facility is equipped to handle every aspect of veterinary care from preventative medicine to emergency services. FloridaWild is part of MVP (Mission Veterinary partners) with more than 330 hospitals and 7800 staff on more than 35 locations in the USA.

For further information please contact:
Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.